Computerized clinical decision system and mobile application with expert support to optimize management of vertigo in primary care: study protocol for a pragmatic cluster-randomized controlled trial

Filipp M. Filippopulos¹² · Doreen Huppert¹ · Thomas Brandt¹ · Margit Hermann³ · Mareike Franz⁴ · Steffen Fleischer⁵ · Eva Grill⁶

Received: 2 May 2020 / Accepted: 10 July 2020 © The Author(s) 2020

Abstract
Vertigo and dizziness are amongst the most common symptoms in medicine and often have a major impact on activities of daily life. Although many causes of vertigo and dizziness can easily be recognized, patients often receive inappropriate and ineffective treatment. The reasons for this are various. Because vertigo/dizziness is an interdisciplinary symptom and there is a lack of standardized diagnostic tools, it is easy to lose the overview of the possible differential diagnoses. There is evidence though, that the management of patients with vertigo/dizziness can be optimized using standardized care pathways with digital support. The present study (within the framework of “PoiSe—prevention, online feedback, and interdisciplinary therapy of acute vestibular syndromes by e-health”) aims to evaluate the implementation of a program with several interlocking components. The three main components are a computerized clinical decision system, a mobile application, a counselling and interdisciplinary educational program developed by the German Center for Vertigo and Balance Disorders (DSGZ). The study is a cluster-randomized controlled trial with a parallel-group design, as well as a detailed process evaluation. Clusters comprise of primary care physician practices in Bavaria, Germany. In the scope of the study the effectiveness, acceptability and efficiency of the intervention will be evaluated. It is anticipated that the intervention will improve the quality and efficiency of the management of dizzy patients. A higher diagnostic accuracy, optimized treatment, and disease progression monitoring is expected to improve patient-relevant outcomes and reduce health-care costs.

Keywords Vertigo · Dizziness · Primary care · Automated clinical decision system

Background
Vertigo and dizziness are amongst the most common key symptoms in medicine. Lifetime prevalence has been shown to lie between 20 and 30% [1, 2]. Claims data from the Bavarian Statutory Health Insurance Physicians’ database showed that over 9% of the adult population received a diagnosis of vertigo annually, most of these in primary care [3]. Disorders of the central or peripheral vestibular system may lead to severe permanent disability.
or to considerable restrictions of daily life [4]. Although most syndromes—as a rule—can be correctly diagnosed and managed by specialists with interdisciplinary training [5], there is still a large discrepancy between recommended and actual management of patients with vertigo [6, 7]. This might lead not only to overuse of health care resources [4, 8], but also to a prolonged clinical course and to the development of chronic complaints or somatization. Notably, primary care physicians perceive diagnosis and treatment of vertigo as complex and challenging while they feel that they risk missing life-threatening conditions such as stroke or neoplasms [7]. Also, while monitoring symptom evolution under treatment, which is of the utmost relevance for the disease management, it has been noted that the resources of a typical primary care consultation are too limited to closely monitor patients with vertigo. Likewise, the narrow view of single aspects of the underlying disorders reflects the compartmentalization of the clinical specializations (neurology, otorhinolaryngology, internal medicine, etc.) with non-uniform clinical guidelines, and insufficient interdisciplinary cooperation [9].

To overcome these problems of management, monitoring and lack of interdisciplinary consultation, various computerized solutions have been proposed. Computerized clinical decision support systems (CCDS) are technologies that aim to optimize clinical decision-making in situations of uncertainty and complexity [10]. Evidence for their effectiveness has been shown for care process parameters such as the ordering of diagnostic tests [11] or medication prescription. Evidence for their effectiveness on patient-reported outcomes, however, is still limited [12]. Secondly, various mobile solutions for the management of chronic disease and risk factors, e.g., for type 2 diabetes [13], bipolar disorders [14], headache [15] or congestive heart failure [16] that have the potential to facilitate monitoring therapy adherence and success are currently being developed. Thirdly, in remote rural areas tele-medicine applications are increasingly used to support primary care decisions with expert advice (e.g., in stroke [17] or emergency medicine [18]; for review see [19]). All these solutions are often implemented as isolated interventions without overarching concept of care and without dedicated evaluation of the implementation processes and their barriers.

We therefore hypothesized that a combination of CCDS with an easy-to-use mobile application and systematic expert support would be able to improve diagnostic accuracy and outcomes of patients presenting with acute vertigo syndromes in primary care, if supported by a large network of different stakeholders.

The objective of this study is therefore to evaluate the implementation of an innovative program with several interlocking components. Specifically, we want to examine the effectiveness, acceptability and efficiency of the new program in primary care.

**Methods**

The study protocol follows the Standard Protocol Items: Recommendations for International Trials (SPIRIT).

**Trial design**

The present study is a cluster-randomized controlled trial with a parallel-group design (PG-CRCT), including a 6-month pilot phase. A detailed process evaluation alongside the trial will be carried out.

Clusters will be primary care practices in Bavaria, one of Germany’s 16 federal states with a population of about 13 millions. Clusters will be randomly assigned in a balanced 1:1 block design to either the intervention or the control group after inclusion into the main study. Concealed allocation of participating practices will be implemented centrally by an independent person that has no knowledge of the practice identity. The randomization sequence will be computer-generated. The size of the practice (number of patients per year) will be considered as a stratification factor. Practices with special focus on vestibular or balance disorders will be excluded.

The study will be submitted to the local ethics committee for approval and prospectively registered in the German Clinical Trials Register (DRKS) before inclusion of the first patient.

**Participants**

**Clusters** Practices in Bavaria will be eligible if they are led by at least one primary care physician and have patients insured by the Allgemeine Ortskrankenkasse Bayern (AOK Bayern), one of the largest health insurance funds in Bavaria with approximately 4.5 millions insured patients. As insured patients are entitled to freely choose their physician and some patients might directly consult medical specialists, neurologists, otorhinolaryngologists and internal medicine specialists will be included in addition to family practitioners.

**Patients** Consenting patients will be eligible for inclusion if they have been referred by at least one primary care physician for acute vertigo or dizziness (ICD-10 codes H81.1–H81.3, H81.8, H81.9, R42 with G63, E53.8, N95.1, G62, I951, H55 or F45.8), are at least 18 years old, and are mentally able to follow instructions. They must also be insured by the AOK Bayern. Patients will be excluded if they are suffering from
a mental illness (e.g. dementia), or a terminal disease with a life expectancy of less than 12 months.

**Intervention**

The intervention consists of three basic components: a web-based platform (CCDS), a mobile application, and a structured system for continuing medical education, expert support and auditing (see Fig. 1).

 Patients presenting with acute vertigo at the physician’s office will be eligible for inclusion in the study. After inclusion, the physician (family practitioner, neurologist, otorhinolaryngologist, internal specialist) will use the CCDS. The patient’s answers to a few basic questions (e.g. How long does the vertigo last?), symptoms (e.g. vomiting) and clinical findings (e.g. horizontal nystagmus) will be analysed by an AI-based algorithm. Subsequently suggestions are offered to the physician for a) a categorization of the possible underlying syndrome (e.g. peripheral vs. central vertigo), b) required diagnostic procedures, c) treatment options, and d) referral to physicians with a different medical speciality (e.g. referral from a family practitioner to a neurologist). Additionally, the physician will receive a warning message when symptoms of a severe underlying disease are noted (e.g. skew deviation in cerebral stroke).

Questionnaires and underlying decision algorithms are based on national and international guidelines and the International Classification of Vestibular Disorders (ICVD) of the Bárány Society.

After the diagnostic process has been completed, the patient is given access to a mobile application (app). This application informs the patient about the underlying disease, supports the therapeutic process and monitors the course of the disease. The app is personalized to the patient’s demographic data (age, gender, language, visual impairment) and to the diagnosis. Furthermore, patients will be instructed to fill out a vertigo/dizziness diary on a daily basis. A newly developed, AI-based algorithm then monitors the information gathered from the diary and correlates it with the individual disease. Additionally, an integrated video documentation and analysis system will analyse eye movements and gait abnormalities by the means of pattern recognition (e.g. neuronal networks, deep learning algorithms) [20–22]. It will be used to objectify the diagnosis and classify patient’s self-recorded symptoms.

In case of an unwanted outcome, e.g. signs of a somatization disorder or no visible improvement of symptoms, the app informs the patient and the physician about this development and suggests that the diagnosis and treatment be reconsidered. The physician additionally has access to an expert network for further support.

The expert network will be established throughout the study period. Physicians with special interest in vestibular disorders, taking geographic criteria into consideration, will be selected to participate in interdisciplinary professional training sessions, video-based case review sessions and consultations by phone. The aim is to create a broad network of physicians that are able to correctly diagnose and treat patients with vertigo/dizziness using an interdisciplinary approach. This is especially relevant for rural areas or regions with a sparse medical network. The expert network overall is intended to complement the digital solution.

The anticipated contents of the three main components are summarized in Fig. 2. The intervention will be tested in a 6-month pilot period. Adaptations of the intervention and the contents after this time-period are possible (see below).
Data collection procedures

Data will be collected at physician (cluster) and patient level. Patient data will be collected at inclusion and after 3 and 6 months. After three months, all patients will be invited to be re-assessed at the German Center for Vertigo and Balance Disorders (DSGZ; see Fig. 1), an outpatient tertiary university unit specialized in the diagnosis and treatment of vertigo and balance disorders. Re-assessments will be blinded to the initial diagnosis and to the study group. Data management will follow the General Data Protection Regulation.

Measures

The outcomes were chosen to measure the effectiveness, acceptability and efficiency of the intervention at provider (cluster) and patient level.

To measure effectiveness at the provider level, the accuracy of diagnoses made by the primary care physician will be evaluated by re-assessment at the DSGZ. Primary effectiveness outcomes at the patient level will be measured using the Dizziness Handicap Inventory (DHI), a validated instrument for measuring disease-specific quality of life and participation in social life [23]. The DHI scores between 0 and 100, with higher scores indicating a decrease in quality of life. Generic quality of life will be measured using the EuroQol-5D (EQ-5D) [24].

The acceptability and feasibility of the intervention will be assessed using a mixed methods approach. Qualitative data will be ascertained by purposeful sampling through individual and group interviews [25]. Quantitative data will be gathered by questionnaires and standardized documentation of the processes throughout the entire study period (including access data generated from the web-platform and the mobile application).

Efficiency will be assessed in terms of the utilization of health care services and the respective costs. To this end, routine data provided by the health insurer AOK Bayern will be linked to individual patient data from the trial. We will concentrate on outpatient visits, hospitalizations, visits to the emergency room, and imaging, because these seem to be the major cost drivers [26].

Process evaluation

Process evaluation will be conducted according to the guidelines of the Medical Research Council (MRC) Framework for evaluating complex interventions [27]. During an initial 6-month pilot period, the acceptance and feasibility of the intervention and its components will be evaluated using a mixed-methods approach. In the following main trial (16 months of recruitment of patients) the processes and quality of the implementation will be evaluated. We will
evaluate various aspects, including the structure and performance of the included practices, implementation fidelity, satisfaction with the intervention and implementation, assessment of scalability, and documentation and assessment of unexpected effects. Auditing will include quality parameters such as study protocol adherence and number of protocol violations, data quality, and adherence to data protection protocols.

**Harms**

The intervention is not expected to lead to any adverse events. Serious unexpected effects believed to be related to the intervention will be collected and recorded according to the GCP from randomization of the first patient through 90 days after the inclusion of the last patient. In this case the intervention will be discontinued, and the patient will be referred to a medical expert.

**Sample size**

A difference of 6–10 points in the DHI with a standard deviation of 20 points is assumed to be a relevant clinical difference. This corresponds to an effect size of between 0.3 and 0.5 [6]. A two-sided t-test for independent groups with an effect size of 0.3, an alpha of 0.05 and beta of 0.20 (power = 80%) results in a sample size of \( n = 352 \) individuals. The inclusion of 10 patients per cluster was assumed with a drop-out rate of 10%, which corresponds to the drop-out rate of similar studies [28, 29]. Therefore, the inclusion of nine patients per cluster was assumed. Taking into account a conservative inter-cluster correlation coefficient (ICC) of 0.04 [30], a design effect (DE) of 1.32 was calculated (DE = 1 + \((k-1) \times ICC\)). This results in a sample size of \( n = 468 \) patients (234 in the intervention program and 234 in the standard care) and thus 52 clusters. At the level of the clusters, a drop-out rate of 2 clusters per study arm can be expected [31]. To further compensate for possible variations in patient recruitment of the clusters, two additional clusters per study arm were considered. Thus, a total of 60 clusters with 600 patients was calculated.

The additional 6-month pilot phase will include 10 clusters with an expected recruitment of 10 patients per cluster (total \( n = 100 \) patients; 50 for each study arm). The aim of the pilot phase is to gather information to optimize the study processes (recruitment, randomisation, data gathering, etc.) and to adapt/improve the CCDS and mobile application. The measured outcomes of the pilot phase will not be included in the evaluation and statistical analysis of the main study.

**Discussion**

We expect that the intervention will improve the quality and effectiveness of the management of patients presenting with acute vertigo or dizziness.

The intervention is expected to optimize the diagnostic decision process, thus, leading to a timely and more effective therapy and a relevant improvement of patient-relevant outcomes. Also, the mobile application will facilitate treatment adherence and symptom management.

Potential limitations that have to be considered include issues of acceptability and usability of the mobile application and interoperability of the web solution. Special needs of persons with disabilities and older persons will have to be considered. This increased diagnostic accuracy and optimized treatment has the potential to improve long term outcomes and reduce health-care costs by reducing the number of diagnostic procedures, the number of consultations, and the treatment costs.

**Acknowledgements**  Open Access funding provided by Projekt DEAL.

We thank Katie Göttlinger for copy-editing the manuscript.

**Funding**  The study is funded by the Federal Joint Committee (G-BA) under the funding ID 01NVF19030.

**Compliance with ethical standards**

**Conflicts of interest**  The authors declare that they have no competing financial interests.

**Ethical approval**  The study will be submitted to the local ethics committee for approval and prospectively registered in the German Clinical Trials Register (DRKS) before inclusion of the first patient.

**Informed consent**  Informed consent will be obtained from all participants in the study in accordance with the Declaration of Helsinki.

**Open Access**  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Neuhäuser H, Radtke A, Von Brevern M, Feldmann M, Lezius F, Ziese T, Lempert T (2006) Migrainous vertigo: prevalence and impact on quality of life. Neurology 67(6):1028–1033

 Springer
2. Yardley L, Owen N, Nazareth I, Luxon L (1998) Prevalence and presentation of dizziness in a general practice community sample of working age people. Br J Gen Pract 48(429):1131–1135
3. Rieger A, Mansmann U, Maier W, Seitz L, Brandt T, Strupp M, Bayer O (2014) Versorgungssituation von Patienten mit dem leit-symptom Schwindel. Das Gesundheitswesen 76(06):e52–e58
4. Neuhauser HK, Radtke A, von Brevern M, Lezius F, Feldmann M, Lempert T (2008) Burden of dizziness and vertigo in the community. Arch Intern Med 168(19):2118–2124
5. Brandt T, Huppert T, Hüfner K, Zingler VC, Dieterich M, Strupp M (2010) Long-term course and relapses of vestibular and balance disorders. Restor Neurol Neurosci 28(1):69–82
6. Grill E, Pengler M, Kentala E (2016) Health care utilization, prognosis and outcomes of vestibular disease in primary care settings: systematic review. J Neurol 263(1):36–44
7. Stephan A-J, Kovacs E, Phillips A, Schelling J, Ulrich SM, Grill E (2018) Barriers and facilitators for the management of vertigo: a qualitative study with primary care providers. Implement Sci 13(1):25
8. Grill E, Strupp M, Müller M, Jahn K (2014) Health services utilization of patients with vertigo in primary care: a retrospective cohort study. J Neurol 261(8):1492–1498
9. Brandt T, Zwergal A, Jahn K, Strupp M (2010) Institutional profile: integrated center for research and treatment of vertigo, balance and ocular motor disorders. Restor Neurol Neurosci 28(1):135–143
10. Haynes R, Wilczynski N (2010) Computerized Clinical Decision Support System (CCDSS) Systematic Review Team Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: methods of a decision-maker-researcher partnership systematic review. Implement Sci 5:12
11. Roshanov PS, You JJ, Dhaliwal J, Koff D, Mackay JA, Weise-Kelly L, Navarro T, Wilczynski NL, Haynes RB (2011) Can computerized clinical decision support systems improve practitioners’ diagnostic test ordering behavior? A decision-maker-researcher partnership systematic review. Implement Sci 6(1):88
12. Sahota N, Lloyd R, Ramakrishna A, Mackay JA, Prorok JC, Weise-Kelly L, Navarro T, Wilczynski NL, Haynes RB (2011) Computerized clinical decision support systems for acute care management: a decision-maker-researcher partnership systematic review of effects on process of care and patient outcomes. Implement Sci 6(1):91
13. Desveaux L, Agarwal P, Shaw J, Hensel JM, Mukerji G, Onabajo M, Marani H, Jamieson T, Bhattacharyya O, Martin D (2016) A randomized wait-list control trial to evaluate the impact of a mobile application to improve self-management of individuals with type 2 diabetes: a study protocol. BMC Med Inform Decis Mak 16(1):144
14. Grünerbl A, Muaremi A, Osmani V, Bahle G, Oehler S, Tröster G, Mayora O, Haring C, Lukowicz P (2014) Smartphone-based recognition of states and state changes in bipolar disorder patients. IEEE J Biomed Health 19(1):140–148
15. Mosadeghi-Nik M, Askari MS, Fatehi F (2016) Mobile health (mHealth) for headache disorders: a review of the evidence base. J Telemed Telecare 22(8):472–477
16. Alhosayen N, Lee E, Alluhaidan A, Chatterjee S, Houston-Feenstra L, Kagoda M, Dysinger W (2014) MyHeart: An intelligent mHealth home monitoring system supporting heart failure self-care. In: 2014 IEEE 16th International Conference on e-Health Networking, Applications and Services (Healthcom), 2014, IEEE, pp 311–316
17. Ickenstein GW, Horn M, Schenkel J, Vatankhah B, Bogdahn U, Haberl R, Audebert H (2005) The use of telemedicine in combination with a new stroke-code-box significantly increases t-PA use in rural communities. Neuroradiol Care 3(1):27–32
18. Brebner E, Brebner J, Ruddick-Bracken H, Wootton R, Ferguson J (2002) Evaluation of a pilot telemedicine network for accident and emergency work. J Telemed Telecare 8(2 suppl):5–6
19. Ekeland AG, Bowes A, Flottorp S (2010) Effectiveness of telemedicine: a systematic review of reviews. Int J Med Inform 79(11):736–771
20. Pradhan C, Wuehr M, Akrami F, Neuhaeusser M, Huth S, Brandt T, Jahn K, Schniepp R (2015) Automated classification of neurological disorders of gait using spatio-temporal gait parameters. J Electromyogr Kinesiol 25(2):413–422
21. Ahmadi A, Destelle F, Unzueta L, Monaghan DS, Linaza MT, Moran K, O’Connor NE (2016) 3D human gait reconstruction and monitoring using body-worn inertial sensors and kinematic modeling. IEEE Sens J 16(24):8823–8831
22. Yiu Y-H, Aboulatta M, Raiser T, Ophey L, Flanigan VL, Zueulenburg P, Ahmadi S-A (2019) DeepVOG: Open-source pupil segmentation and gaze estimation in neuroscience using deep learning. J Neurosci Methods 324:108307
23. Kurre A, van Gool CJ, Bastiaenen CH, Gloor-Juzi T, Straumann D, De Bruin ED (2009) Translation, cross-cultural adaptation and reliability of the German version of the Dizziness Handicap Inventory. Otol Neurotol 30(3):359–367
24. Herdman M, Gudex C, Lloyd A, Jansen S, Kind P, Parkin D, Bonsel G, Badia X (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20(10):1727–1736
25. Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K (2015) Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. Adm Policy Ment Health 42(5):533–544
26. Kovacs E, Wang X, Grill E (2019) Economic burden of vertigo: a systematic review. Health Econ Rev 9(1):1–14
27. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, Moore L, O’Cathain A, Tinati T, Wright D (2015) Process evaluation of complex interventions: Medical Research Council guidance. BMJ 350:h2158
28. Menant JC, Migliaccio AA, Sturnieks DL, Hicks C, Lo J, Ratnapoglake M, Turner J, Delbaere K, Titov N, Meinrath D (2018) Reducing the burden of dizziness in middle-aged and older people: a multifactorial, tailored, single-blind randomized controlled trial. PLoS Med 15(7):e1002620
29. van Vuigt VA, van der Woude JC, Essery R, Yardley L, Twisk JW, van der Horst HE, Maarsingh OR (2019) Internet based vestibular rehabilitation with and without physiotherapy support for adults aged 50 and older with a chronic vestibular syndrome in general practice: three armed randomised controlled trial. BMJ 367:l5922
30. Littenberg B, MacLean CD (2006) Intra-cluster correlation coefficients in adults with diabetes in primary care practices: the Vermont Diabetes Information System field survey. BMC Med Res Methodol 6(1):20
31. Rutherford C, Copas A, Eldridge S (2015) Methods for sample size determination in cluster randomized trials. Int J Epidemiol 44(3):1051–1067